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ABSTRACT
Update of the recommendations of the Fertility Preservation Working Group in Oncological, Hematological and Other 
Patients Treated with Gonadotoxic Therapies “ONCOFERTILITY” (GROF) of the Polish Society of Oncological Gynecology 
regarding cryopreservation and autologous ovarian tissue transplantation.
The Fertility Preservation Working Group in Oncological, Hematological and Other Patients Treated with Gonadotoxic 
Therapies “ONCOFERTILITY” (GROF) of the Polish Society of Oncological Gynecology has developed current clinical guide-
lines and recommendations to improve the quality of healthcare provision in the area of reproductive health in patients 
undergoing therapy that may impair their reproductive potential.
The guidelines are based on current scientific evidence available at the time of writing this document. In the absence of 
scientific evidence on some aspects, a consensus was reached among GROF stakeholders.
The purpose of the guidelines is to assist healthcare professionals in making decisions in specific clinical situations regard-
ing the selection of an appropriate and effective diagnostic and therapeutic process. The document provides practical 
guidelines for the management of cryopreservation and autologous ovarian tissue transplantation.
Ginekologia Polska 2021; 92, 9: 668–672
INTRODUCTION
In fewer and fewer countries, using ovarian tissue 
cryopreservation (OTC) as a method of preserving fertility 
in women who require chemotherapy is still considered 
an experimental treatment. In Poland, in accordance with 
the 2017 recommendations of the Polish Cancer Society’s 
Working Group for the Preservation of Fertility in Cancer 
Patients (GROF), it was recommended that OTC be used only 
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in centers with appropriate experience [1], using protocols 
approved by the Bioethics Committee.
However, due to the increasing use of OTC as a method 
of securing fertility prior to systemic treatment around the 
world and increasing evidence of its effectiveness, this 
method is no longer considered a medical experiment. 
In the 2019 recommendations of the Executive Committee 
of the American Society for Reproductive Medicine (ASRM) 
[2], we read that OTC is no longer considered an experi-
mental method and is the only option for prepubertal girls 
and those women who cannot be stimulated for an IVF 
procedure. The European Society of Human Reproduction 
and Embryology (ESHRE) has also changed its position on 
OTC and in the recommendations of 2020 [3] we read that 
ovarian tissue freezing may be proposed as an alternative 
treatment to preserve fertility in young patients who are at 
risk of developing premature ovarian insufficiency (POI).
 
ADVANTAGES AND LIMITATIONS OF OTC 
(OVARIAN TISSUE CRYOPRESERVATION) 
OTC can be used in prepubertal girls, in women who do 
not have time or are not advised to stimulate ovulation prior 
to oncological intervention and in those who do not accept 
assisted reproductive techniques. In addition, it should be 
noted that the collection and retransplantation of ovar-
ian tissue (OTT) is the only method of securing fertility that 
allows conception without further medical interventions. 
It is also a method of restoring the hormonal function of 
the ovary and, consequently, a cardioprotective effect, 
reducing the risk of osteoporosis and senile dementia, 
which with such a high percentage of autograft acceptance 
(95%) seems no less important than procreation itself [4]. 
The disadvantage of this method is the necessity to perform 
laparoscopy at least twice and the lack of reimbursement of 
costs of freezing ovarian tissue from public funds in Poland. 
In the case of hematological neoplasms, there is a theoretical 
risk related to the possibility of re-implantation of neoplastic 
cells in a frozen fragment of the ovary (depending on the 
type and stage of the neoplasm), but so far, no such case 
has been reported. [5]. Due to the risk of retransplantation of 
neoplastic cells in patients with haematological neoplasms, 
the collection of ovarian tissue in this group should be per-
formed only after induction chemotherapy and complete 
remission of the tumor in the blood.
EFFECTIVENESS 
OTC indications and exclusion criteria differ depending 
on the centers that carry them out. The age of the enrolled 
patients seems to be crucial. In various recommendations, 
we find the upper age limit from 35 years [6] to even 49 years 
[7–9]. However, pregnancy was rarely achieved in women 
over 35 years of age, and none over 38 years of age was 
found [10]. The effectiveness of this method for women 
younger than 36 years is confirmed by the study, which 
compared the effectiveness of OTC in comparison with 
oocyte cryopreservation (OC). It showed the superiority 
of OC for women over 36 years of age, in whom 30% of 
pregnancies obtained with this method were found, while 
no pregnancies were achieved with the OTC method. In the 
group of younger patients, the effectiveness of both meth-
ods was comparable [11]. By 2019, autologous ovarian tissue 
transplantation was performed in over 300 patients, over 
140 pregnancies obtained by this method were reported, 
of which over 100 children were born. In 85% of cases, ovar-
ian tissue cryotransplant function was restored within four 
months. The effectiveness of the method was assessed at 
40%, counting at least one child per patient treated with 
this method [10, 12]. More recent data estimate the effi-
cacy of ovarian tissue autograft measured as restoration of 
menstrual function and a reduction in FSH < 20 IU/mL as 
94%, while the return of procreative function, measured as 
at least one pregnancy, was estimated at 50%, and delivery 
to nearly 42% [4]. Unfortunately, there is no data on the 
number of babies born for all women who started treatment 
with this method, and a relatively low number of procedures 
performed. The largest percentage of patients undergoing 
the OCT procedure are patients with breast cancer. In this 
group of women, the damage to the ovarian tissue structure 
as a result of chemotherapy occurs not only by damaging 
the DNA structure in egg cells and granular cells, but also 
by accelerating the recruitment of primordial follicles [13]. 
Recently, the loss of the ovarian reserve through oocyte 
apoptosis has also been postulated [14]. Therefore, it seems 
that special emphasis should be placed on the collection 
of ovarian tissue before the implementation of systemic 
therapy in neoplasms other than hematological.
OVARIAN FRAGMENT CRYOPRESERVATION 
PROCEDURE — OTC
There are two methods of collecting ovarian tissue:
1. Ovarian cortex biopsy 1/3–2/3 ovarian surface (OCB), 
used for large ovaries or high ovarian reserve (AMH > 2).
2. Unilateral removal of the ovary in the case of low ovar-
ian reserve, small ovaries.
The treatment can be performed on any day of the 
cycle. The collected tissue must be transported to the refer-
ence embryology laboratory under strict conditions within 
1–20 hours [5].
There are no studies comparing the effectiveness of 
both methods of obtaining ovarian tissue. The advantage 
of OCB is that it leaves both ovaries as a potential site for 
ovarian tissue transplantation and reduces the invasiveness 
of the procedure. A potential disadvantage of removing 
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one ovary is the acceleration of menopause after chemo-
therapy/radiotherapy, although no comparative studies 
have been performed in these groups of patients [10].
Preparation for cryopreservation consists of dividing 
the ovarian cortex in sterile conditions into fragments of ap-
proximately 1 mm. This is because effective freezing requires 
tissue thickness up to 2 mm, and that the vast majority of 
primordial follicles are located less than 1 mm from the ovary 
surface. The fragments prepared in this way are individu-
ally frozen by slow freezing or vitrification. The 2018 study 
describes the recovery of pregnancy from ovarian tissue 
retransplantation, frozen using the slow-freezing method 
and stored for over 14 years. Since the procedure of ovar-
ian tissue collection cannot be repeated, the preparation 
and freezing of the tissue should be performed by trained 
embryologists and in appropriately adapted laboratories.
OVARIAN TISSUE TRANSPLANTATION (OTT)
Autotransplantation of ovarian fragments can be done 
either orthotropically or heterotropically. The orthotropic 
sites are the remaining ovaries, the broad ligament, and the 
peritoneal pocket at the ovary. There were no significant 
differences between these sites [10].
Heterotropic sites for autotransplantation of ovar-
ian fragments have been described, such as the subcuta-
neous tissue of the forearm and abdominal integuments, or 
only one birth from heterotropic transplantation [15], while 
the rest from orthotropic location, with as many as 60% of 
these pregnancies conceived naturally.
Patients who became pregnant after OTT were on average 
younger than those who failed (26.4 ± 6.3 vs 29.6 ± 5.4 years) 
[10]. One group describes the inclusion criteria for OCT based 
on the age of patients under 35 years of age and the mea-
surement of ovarian reserve (AMH above 0.4 ng/mL and 
AFC > 5 antral follicles) [16]. The average ovarian transplant 
lifetime is 24.9 month (4–144 months), three live births over 
seven years after OTT were described in one patient [10].
There is no consensus on the amount/volume of ovar-
ian tissue transplanted. In a meta-analysis of 309 OTT, 
255 women had 1/3 ovaries transplanted, and 45 patients 
who required two transplants to become pregnant were 
also reported. Three such procedures were described in 
only one percent of cases. There is also no universally ac-
cepted upper age limit for women undergoing OTT. The 
oldest reported patients were 47 years old and in these 
cases, attention is drawn to the maternal risk associated 
with pregnancy [10, 17].
OTHER METHODS COMBINED WITH OTC
In order to increase the chances of getting pregnant, the 
ESHRE recommendations allow the combination of OTC with 
other fertility preservation techniques, such as OC (oocyte 
cryopreservation) and the movement of the ovaries beyond 
the small pelvis when irradiation in this area is necessary. 
In the case of oocyte cryopreservation, it is recommended 
to stimulate ovulation immediately after the OTC procedure 
or immediately before [3]. 
SAFETY OF THE METHOD 
Surgical complications 
Both the collection of ovarian tissue and its retransplan-
tation are associated with a low risk of surgical complica-
tions, estimated at about one percent [18, 19]. Retransplan-
tation surgery may be combined with other procedures, 
such as hysteroscopy, tubal patency assessment, and other 
procedures depending on the clinical context. It is recom-
mended that the OTT procedure and ovarian thawing take 
place in the same facility. Although there are no reports of 
infectious complications, it is recommended to consider 
prophylactic perioperative antibiotic therapy. 
Risk of reintroducing cancer cells 
Ovarian metastases are found in slightly more than 20% 
of autopsies in women who died due to non-gynecological 
neoplastic diseases. For this reason, the decision about OTT 
should be made with utmost caution in patients suffering 
from leukemia and CSN neoplasms, such as medulloblas-
toma or neuroblastoma. In other neoplasms, OTT seems safe 
if the invasion of small pelvis is excluded. For this reason, 
it seems unlikely that the risk of reintroduction of cancer 
cells in ovarian and adnexal cancers (even in the case of graft 
removal after pregnancy) could be so limited that OTT could 
be recommended as safe in these cancers. Before OTT, the 
patient should be in good condition and cured oncologically 
in accordance with the accepted treatment criteria. After 
retransplantation, she should be subject to at least two years 
of oncological follow-up [5]. It seems reasonable to perform 
a histopathological examination of an ovarian section taken 
during the OTC procedure, as well as another histopatho-
logical inspection before cryopreservation of the tissue.
Perinatal complications
Recent meta-analyzes in patients after cancer treatment 
indicate an increased risk of prematurity (RR 1.56; 95% CI 
1.37–1.77 — mainly due to oncological indications for early 
termination of pregnancy), low birth weight (RR 1.47; 95% CI 
1.24–1.73), urgent Caesarean sections (1.22; 95% CI 1.15–1.30), 
elective cesarean sections (RR 1.38; 95% CI 1.13–1.70), and 
postpartum haemorrhages (RR 1.18; 95% CI 1.02–1.36) [20].
Risk to the fetus
There is no evidence of an additional risk of fetal mal-
formations after OTT [10, 21]. The risk is about 1.2%, which 
is comparable with the occurrence of major fetal malforma-
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tions in the general population [17]. The latest data on the 
occurrence of fetal malformations in 22 patients who under-
went the first course of chemotherapy before OTC indicate 
the birth of eight healthy children from 13 pregnancies [22].
Long-term risk
As the first cryotransplantation took place almost 
20 years ago and there are no reports of negative breasts re-
lated to this method, the long-term risk should be assumed 
to be low. A separate problem is patients treated for breast 
cancer with mutations in the BRCA1 or BRCA2 genes. In 
these patients, a site of transplantation (heterotropic trans-
plantation) may be considered, where the observation of the 
graft will be easier, or orthotropic transplantation, followed 
by removal of the appendages, as soon as possible after 
birth, to the number of children that the patient established, 
but not later than the age of 40 [23, 24].
RECOMMENDATIONS OF THE WORKING 
GROUP
1. The Working Group recommends the recognition of the 
OTC/OTT procedure as a therapeutic method.
2. It is recommended to consider OTC/OTT in patients with 
low ovarian reserve (AMH < 0.4 ng/mL, AFC < 5 follicles 
in both ovaries)
3. In the case of blood cancers and CSN, individual con-
sideration of the case regarding the risk of tumor reim-
plantation seems justified.
4. It is recommended to use OTC after the initiation of 
chemotherapy only for hematological malignancies
FINAL REMARKS
The guidelines do not replace and do not override 
the individual responsibility of healthcare profession-
als to make the right decisions about the diagnosis 
and treatment of individual patients. Ultimately, it is 
healthcare professionals who make clinical decisions on 
a case-by-case basis, using their clinical judgment, knowl-
edge and experience, and considering the condition, 
circumstances and wishes of the patient, in consulta-
tion with the patient and/or their caregiver and taking 
into account current guidelines issued by relevant public 
health organizations.
The team of experts reserves the right to update this 
statement in the event of new significant scientific reports.
These GROF guidelines are published for educational 
use only. Commercial use is not permitted. No part of the 
guidelines may be translated or copied in any form without 
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